Literature DB >> 10555654

Cerebrospinal fluid creatine kinase-BB isoenzyme activity and outcome after subarachnoid hemorrhage.

W M Coplin1, W T Longstreth, A M Lam, W L Chandler, T S Mayberg, J S Fine, H R Winn.   

Abstract

BACKGROUND: The brain is rich in creatine kinase-BB isoenzyme activity (CK-BB), which is not normally present in cerebrospinal fluid (CSF). Results of previous studies have shown that CK-BB can be detected in the CSF of patients with aneurysmal subarachnoid hemorrhage (SAH), but whether CK-BB levels correlate with patients' neurologic outcomes is unknown.
OBJECTIVE: To evaluate the relationship between CSF CK-BB level and outcome after SAH.
DESIGN: Prospective observational cohort.
SETTING: University-affiliated tertiary care center. PATIENTS: Convenience sample of 30 patients seen for cerebral aneurysm clipping.
INTERVENTIONS: We sampled and assayed CSF for CK isoenzymes a median of 3 days after SAH in 27 patients, and at the time of unruptured aneurysm clipping in 3 patients. MAIN OUTCOME MEASURES: Without knowledge of CK results, we assigned the Glasgow Outcome Scale score early (approximately 1 week) and late (approximately 2 months) after surgery.
RESULTS: Higher CSF CK-BB levels were associated with higher Hunt and Hess grades at hospital admission (Spearman rank correlation, p = 0.69; P<.001), lower Glasgow Coma Scale scores at hospital admission (p = -0.72; P<.001), and worse early outcomes on the Glasgow Outcome Scale (p = -0.64; P<.001). For patients with a favorable early outcome (Glasgow Outcome Scale score, 3-5), all CK-BB levels were less than 40 U/L. With a cutoff value of 40 U/L, CK-BB had a sensitivity of 70% and a specificity of 100% for predicting unfavorable early outcome (Glasgow Outcome Scale score, 1-2). Having a CK-BB level greater than 40 U/L increased the chance of an unfavorable early outcome, from 33% (previous probability) to 100%, whereas a CK-BB level of 40 U/L or less decreased it to 13%. Similar findings were obtained when considering late outcomes.
CONCLUSION: The level of CSF CK-BB may help predict neurologic outcome after SAH.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10555654     DOI: 10.1001/archneur.56.11.1348

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  7 in total

Review 1.  Predictive biomarkers of recovery in traumatic brain injury.

Authors:  Sabrina Giacoppo; Placido Bramanti; Marina Barresi; Debora Celi; Valeria Foti Cuzzola; Eleonora Palella; Silvia Marino
Journal:  Neurocrit Care       Date:  2012-06       Impact factor: 3.210

Review 2.  Biomarkers as outcome predictors in subarachnoid hemorrhage--a systematic review.

Authors:  Caron M Hong; Cigdem Tosun; David B Kurland; Volodymyr Gerzanich; David Schreibman; J Marc Simard
Journal:  Biomarkers       Date:  2014-02-05       Impact factor: 2.658

3.  Biospecimens and Molecular and Cellular Biomarkers in Aneurysmal Subarachnoid Hemorrhage Studies: Common Data Elements and Standard Reporting Recommendations.

Authors:  Sherry H-Y Chou; R Loch Macdonald; Emanuela Keller
Journal:  Neurocrit Care       Date:  2019-06       Impact factor: 3.210

4.  Death is associated with complement C3 depletion in cerebrospinal fluid of patients with pneumococcal meningitis.

Authors:  U R Goonetilleke; M Scarborough; S A Ward; S Hussain; A Kadioglu; S B Gordon
Journal:  mBio       Date:  2012-03-13       Impact factor: 7.867

5.  Biochemical changes in the injured brain.

Authors:  Seelora Sahu; Deb Sanjay Nag; Amlan Swain; Devi Prasad Samaddar
Journal:  World J Biol Chem       Date:  2017-02-26

6.  A blood-based biomarker panel to risk-stratify mild traumatic brain injury.

Authors:  Richa Sharma; Alexandra Rosenberg; Ellen R Bennett; Daniel T Laskowitz; Shawn K Acheson
Journal:  PLoS One       Date:  2017-03-29       Impact factor: 3.240

Review 7.  Monitoring biomarkers of cellular injury and death in acute brain injury.

Authors:  Sherry H-Y Chou; Claudia S Robertson
Journal:  Neurocrit Care       Date:  2014-12       Impact factor: 3.210

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.